Back to Directory

AVIPERO Bio

Founded 2009
Antibody therapeutics targeting β1 integrin in metastatic cancer

AVIPERO Bio is a biopharmaceutical company developing allosteric modulators of integrins for metastatic cancer and fibrotic disease. Its lead candidate, AVI001, is a humanised monoclonal antibody designed to stabilise β1 integrin in a low-affinity state. The programme investigates how modifying integrin activity affects tumour invasion. The company lists AVI001 at lead optimisation and a second programme, AVI002, at hit identification for fibrotic disease.